Data di Pubblicazione:
2023
Citazione:
Outcome of BCG Vaccination in ADA-SCID Patients: A 12-Patient Series / Canarutto, D.; Oltolini, C.; Barzaghi, F.; Calbi, V.; Migliavacca, M.; Tucci, F.; Gallo, V.; Consiglieri, G.; Ferrua, F.; Recupero, S.; Cervi, M. C.; Al-Mousa, H.; Pituch-Noworolska, A.; Tassan Din, C.; Scarpellini, P.; Silvani, P.; Fossati, C.; Casiraghi, M.; Cirillo, D. M.; Castagna, A.; Bernardo, M. E.; Aiuti, A.; Cicalese, M. P.. - In: BIOMEDICINES. - ISSN 2227-9059. - 11:7(2023), p. 1809. [10.3390/biomedicines11071809]
Abstract:
Vaccination with Bacillus Calmette–Guérin (BCG) can be harmful to patients with combined primary immunodeficiencies. We report the outcome of BCG vaccination in a series of twelve patients affected by adenosine deaminase deficiency (ADA-SCID). BCG vaccination resulted in a very high incidence of complications due to uncontrolled replication of the mycobacterium. All patients who developed BCG-related disease were treated successfully and remained free from recurrence of disease. We recommend the prompt initiation of enzyme replacement therapy and secondary prophylaxis to reduce the risk of BCG-related complications in ADA-SCID patients.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
enzyme replacement therapy; gene therapy; isoniazid; newborn screening; rifampin; tuberculosis
Elenco autori:
Canarutto, D.; Oltolini, C.; Barzaghi, F.; Calbi, V.; Migliavacca, M.; Tucci, F.; Gallo, V.; Consiglieri, G.; Ferrua, F.; Recupero, S.; Cervi, M. C.; Al-Mousa, H.; Pituch-Noworolska, A.; Tassan Din, C.; Scarpellini, P.; Silvani, P.; Fossati, C.; Casiraghi, M.; Cirillo, D. M.; Castagna, A.; Bernardo, M. E.; Aiuti, A.; Cicalese, M. P.
Link alla scheda completa:
Link al Full Text:
Pubblicato in: